VUNO Announces Early Dementia Diagnosis Using Medical AI... Research Results Presented at AAIC

Research Results Utilizing VunoMed DeepBrain®
Correlation of Alzheimer's Risk Factors in Patients with Subjective Cognitive Decline

Medical AI company VUNO announced on the 12th that it will participate in the world's largest global conference on Alzheimer's disease, AAIC, held in Amsterdam, Netherlands, from the 16th to the 20th.

VUNO will present research results using its AI-based brain quantification medical device, VUNO Med-DeepBrain®. VUNO Med-DeepBrain® is an AI medical device that analyzes brain MRI images based on deep learning, parcellating the brain into more than 100 regions and providing quantified information on the degree of atrophy in each region within one minute. It helps medical professionals accurately understand the patient's condition and contributes to the early screening of patients who may have dementia.

Based on the brain atrophy analysis results of VUNO Med-DeepBrain®, VUNO will present research results that predict amyloid beta protein positivity in the brains of patients with Subjective Cognitive Decline (SCD) and demonstrate the early diagnostic performance of the product for Alzheimer's disease. Subjective Cognitive Decline refers to a subtle decline in brain function subjectively experienced by patients in memory, cognitive ability, learning ability, concentration, etc. It is considered a stage prior to Mild Cognitive Impairment (MCI) or early dementia and is known to be important for early detection and management due to the possibility of progression to dementia.

To identify Alzheimer's disease risk factors early in patients with Mild Cognitive Impairment or early dementia, PET (Positron Emission Tomography) scans are performed to check the accumulation level of amyloid beta protein in the brain. However, this test is costly and not widely available in many hospitals, limiting patient accessibility.

VUNO Med-DeepBrain® provides information on the degree of atrophy in different brain regions based on brain MRI, which is relatively low-cost and more accessible, allowing for easier and more accurate assessment of the patient's condition. The VUNO research team's study is significant in that it suggests the possibility of early diagnosis of Alzheimer's disease even in patients with Subjective Cognitive Decline, an early stage before full dementia symptoms appear.

At AAIC, VUNO plans to promote the clinical excellence of VUNO Med-DeepBrain® and expand partnerships by increasing engagement with on-site participants. The product obtained European CE certification in 2020, and the FDA approval process for entry into the U.S. market is currently underway.

Yea-ha Lee, CEO of VUNO, said, "We are able to showcase the excellence of VUNO Med-DeepBrain®, which is about to enter the U.S. market, and VUNO's research and development capabilities at the largest conference in the Alzheimer's field." She added, "We will continue to strive to provide various supportive information for dementia diagnosis to medical professionals in diverse clinical settings worldwide to help solve dementia-related issues."